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AbSTrACT
Objectives counting intraepithelial lymphocytes 
(iel) is central to the histological diagnosis of 
coeliac disease (cD), but no definitive ’normal’ iel 
range has ever been published. in this multicentre 
study, receiver operating characteristic (rOc) curve 
analysis was used to determine the optimal cut-off 
between normal and cD (Marsh iii lesion) duodenal 
mucosa, based on iel counts on >400 mucosal 
biopsy specimens.
Design the study was designed at the international 
Meeting on Digestive Pathology, Bucharest 2015. 
investigators from 19 centres, eight countries of 
three continents, recruited 198 patients with Marsh 
iii histology and 203 controls and used one agreed 
protocol to count iel/100 enterocytes in well-oriented 
duodenal biopsies. Demographic and serological data 
were also collected.
results the mean ages of cD and control groups 
were 45.5 (neonate to 82) and 38.3 (2–88) years. 
Mean iel count was 54±18/100 enterocytes in cD and 
13±8 in normal controls (p=0.0001). rOc analysis 
indicated an optimal cut-off point of 25 iel/100 
enterocytes, with 99% sensitivity, 92% specificity and 
99.5% area under the curve. Other cut-offs between 
20 and 40 iel were less discriminatory. additionally, 
there was a sufficiently high number of biopsies to 
explore iel counts across the subclassification of the 
Marsh iii lesion.
Conclusion Our rOc curve analyses demonstrate 
that for Marsh iii lesions, a cut-off of 25 
iel/100 enterocytes optimises discrimination between 
normal control and cD biopsies. no differences in 
iel counts were found between Marsh iii a, b and 
c lesions. there was an indication of a continuously 
graded dose–response by iel to environmental (gluten) 
antigenic influence.
InTrODuCTIOn
Coeliac disease (CD) has a large spectrum of clin-
ical and histological presentations. The accompa-
nying structural changes in the upper small intestinal 
mucosa range through normal or near-normal to 
severe changes where partially reduced villi amal-
gamate into large, lozenge-shaped surface plateaus.1 
As the mucosa ‘flattens’, these markedly hypertro-
phic responses are triggered by lamina propria T cells 
under genetic control. Intraepithelial lymphocytes 
(IEL) lying within the epithelium, and surveying both 
lumen and lamina propria, are also implicated in this 
process,2 although their functions and prognostic 
value still remain somewhat undecided. An increased 
population of IEL has, for almost five decades, 
provided a sensitive histological pointer towards CD 
diagnosis, made more important over the years by 
the Marsh classification and its emphasis on the infil-
trates in normal-looking, villus-bearing mucosa.3
CD is not the only intestinal condition associated 
with increased IEL counts, which has resulted in the 
view that a lymphocytosis characterising the milder 
Marsh I and II lesions can be dismissed as ‘non-spe-
cific’. To overcome this impasse, a recent paper 
dealing with the differential diagnosis of these 
lymphocytic infiltrates was recently published by 
the Bucharest Consensus4 and collectively defined 
as microscopic enteritis.
The Bucharest Consensus was primarily concerned 
with subtle submicroscopic changes and IEL in 
coeliac and non-coeliac mucosae. However, despite 
the numerous papers written on this subject, we 
were concerned that the literature lacks a definitive 
cut-off point to confirm the diagnosis. First, there is 
no universal definition for a ‘normal’ IEL range, and 
so this makes it difficult to define a specific point of 
departure favouring a histological diagnosis of CD.
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The earliest paper5 used very thick H&E sections (5–7 µm) 
which are not ideal for making accurate counts, while 
suggesting that IEL populations are normally distributed. 
An extremely high cut-off of 40 IEL/100 enterocytes was 
proposed. Various immunohistochemical approaches have also 
been deployed since that time, but never incorporated into 
routine practice.6 Moreover, despite its apparent sophistication 
and derived insights, the use of immunohistochemistry can be 
time consuming, requiring additional laboratory techniques 
and technologies which, when services are under severe time 
and financial constraints, may not necessarily be ideal. More-
over, since these techniques have not yielded increased degrees 
of diagnostic precision, they have not yet become cemented 
into routine clinical practice.
There is therefore a very strong case for re-examining existing 
laboratory procedures based on H&E-stained sections, thus to 
improve diagnostic accuracy beyond currently held perceptions. 
This study aims to bring clarity to the situation. In addition, our 
differential IEL counts offer further unexpected insights into 
mucosal biopsy interpretation.
MeThODS AnD MATerIAlS
This case–control study was designed during the International 
Meeting on Digestive Pathology held in Bucharest, November 
2015. It is a multicentred international study involving eight 
countries, comprising 19 laboratories, each of which provided 
histological reviews of 10 patients with CD and 10 disease control 
(DC) patients. The 19 participating centres provided their data 
from Europe, Middle East and America, which included Ancona, 
Bologna, Brescia, Salerno, Perugia, Milan and Sciacca (Italy); 
Dudley, Glasgow, Luton and Milton Keynes (UK); Mashhad and 
Tehran (Iran); Amsterdam (The Netherlands); Ankara (Turkey); 
Bucharest and Iasi (Romania); Lyon (France) and Boston (USA). 
In total, this provided assessments on 401 biopsy specimens and 
IEL counts on 198 patients with CD (142 (71.7%) women and 
56 (28.3%) men) and 203 DC patients (120 (59.1%) women 
and 83 (40.9%) men). The CD and DC biopsies were selected 
if they had 4–6 well-oriented tissue samples to allow evaluation 
of villous/crypt ratio and the number and distribution of the 
lymphocytes. The number of IEL/100 epithelial cell nuclei was 
counted in a continuous manner, leaving out the crypt openings. 
Each laboratory reanalysed the quality of cases before sending 
the results centrally for consolidation and review. Prominent 
clinical features relevant to each group are listed (table 1). The 
inclusion criteria for recruitment were positive coeliac serology 
and typical histological abnormalities consistent with Marsh III 
changes.3 7 The subjects with DC were selected from patients with 
iron deficiency and a negative coeliac serology. Exclusion criteria 
for DC included active infections, for example, Helicobacter 
pylori or bacterial overgrowth, non-steroidal anti-inflammatory 
drugs use, food allergy or any other small bowel disorders. In 
this retrospective study, H&E-stained 4–5 µm thick sections cut 
from formalin-fixed paraffin-embedded archival material were 
used in 162 cases. Some centres additionally employed CD3 
immunohistochemistry, involving 36 patients, using commer-
cially available anti-CD3 antibodies. The CD3 antibody clone 
and vendor and dilutions were different in each centre.8
The project aimed to measure the number of IEL/100 entero-
cytes in well-oriented duodenal biopsies from patients with 
untreated CD compared with a corresponding number of DC 
Table 1 Frequency of symptoms/sign among patients with coeliac 
disease and disease control subjects
Symptoms/signs
Patients with coeliac 
disease (n=198)
Disease control subjects 
(n=203)
Weight loss 13 (6.57)* 8 (3.94)
Diarrhoea/very loose stool 68 (34.24) 13 (6.40)
Iron deficiency anaemia 54 (27.27) 64 (31.53)
Abdominal pain 26 (13.13) 26 (12.81)
Reflux 7 (3.53) 43 (21.18)
Vomiting 2 (1.01) 5 (2.46)
Bloating 16 (8.08) 10 (4.93)
Constipation 5 (2.53) 0
Thyroiditis 5 (2.53) 0
short stature 6 (3.03) 2 (0.99)
Fatigue 2 (1.01) 2 (0.99)
Hypertransaminasaemia 1 (0.51) 0
Short stature 1 (0.51) 0
Epilepsy 1 (0.51) 0
Osteoporosis 1 (0.51) 0
Note: A low ferritin was found in 27% of patients with CD; however, 15% of cases 
had anaemia as their main presenting symptoms.
*Number (%).
Significance of this study
What is already known on this subject?
 ► Increased population of intraepithelial lymphocytes (IEL) 
provides a sensitive histological pointer towards coeliac 
disease (CD) diagnosis.
 ► IEL lying within the epithelium, and surveying both lumen 
and lamina propria, are implicated in disease activity, but 
their functions and prognostic value still remain somewhat 
undecided.
 ► Submicroscopic changes of epithelial cells and the differential 
diagnosis of lymphocytic infiltrates were collectively defined 
as microscopic enteritis.
What are the new findings?
 ► We show that an effective cut-off can be obtained with 
receiver operating characteristic curve analysis, which 
substantially reduces the overlap between CD and normal 
controls.
 ► We confirm that counting of IEL performed on H&E-stained 
material provides optimal results, compared with CD3/γδ 
immunostained sections.
 ► We have graphically represented the cumulative totals of 
IEL across all our biopsies, revealing a continuous ‘dose–
response’ curve reflective of the IEL response to luminal 
antigen, rather than a biphasic or clonal response that might 
have distinguished controls from coeliac. This has never been 
demonstrated before.
 ► Finally, with a reliable, large sample, our differential counts 
revealed no differences between Marsh III a, b and c, 
indicating that the subdivision of Marsh III has no practical 
value.
how might it impact on clinical practice in the foreseeable 
future?
 ► Our differential IEL counts offer unexpected insights into 
mucosal interpretation that will improve diagnostic accuracy. 
These include bringing clarity to the IEL’s implications in 
CD histogenesis, subdivision of Marsh III, assessing the 
diagnostic role of immunohistochemistry and proposing an 
effective cut-off to separate disease control from CD.
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subjects. A definitive diagnosis of CD was defined as those patients 
demonstrating Marsh III histological abnormalities with positive 
serology in line with the current and previous guidelines, whereas 
those with seronegative Marsh III lesions were excluded.9 10 A 
multi-institutional collaborative effort to define optimal cut-offs to 
diagnose CD in patients with milder mucosal changes (Marsh I–II) 
is being planned as follow-up to our current study.
ethical considerations
This study involved re-scoring of archived histology slides, and 
all identifiable medical information was removed and all analyses 
were performed using anonymised data. The data collection was in 
line with good clinical practice policies with approval by research 
and development/audit departments of countries involved. The 
study was also fully approved by the ethical committee of Research 
Institute for Gastroenterology and Liver Disease, Shahid Beheshti 
University of Medical Science, Tehran under the following ethical 
number: IR.SBMU.RIGLD.REC.1395.87.
Statistical analysis
Data are reported as mean (±SD) for continuous variables and as 
proportion for categorical variables. Comparisons were performed 
using the Student’s t-test or χ2 test, as appropriate. Receiver oper-
ating characteristic (ROC) curves were used to evaluate sensitivity 
and specificity for different cut-off levels of IEL/100 in detecting 
CD. Statistical significance was set at α=0.05.
reSulTS
The mean ages of DC and CD groups were 38.3 (range: 2–88) and 
45.5 years (range: newborn to 82), respectively, of which 59% 
and 71% were women. The mean IEL count was 54±18/100 
enterocytes for CD compared with 13±8 for DC (p=0.0001). 
We present data (figure 1) from IEL counts based on the largest 
series of intestinal biopsies analysed to date, obtained from eight 
countries across three continents (North America, Europe and 
Middle East). In total, 401 specimens were studied, of which 
198 came from well-defined patients with CD who were either 
endomysial antibodies (EMA) or tissue transglutaminase anti-
bodies (tTG) antibody positive (table 1). Of the 198 patients 
with CD with Marsh III, 27% had iron deficiency anaemia, 13% 
abdominal pain, 34% diarrhoea and 6% weight loss (table 1).
The mean±SD for the DC was 13±7 IEL/100 enterocyte 
nuclei (95% CIs 1–27). The normality of the variable was 
assessed visually using a histogram/assessed using a Shapiro-Wilk 
test which confirmed that the data are skewed to the right and 
distinctly non-normal. The mean IEL count for CD was 54±18 
(95% confidence limits 19–54), differing significantly from DC 
(p<0.0001). The ‘normalised’ CD mean was 51±14 (95% confi-
dence limits 24–78). Overall, using numerical data, CD and DC 
biopsies showed an overlap of 56 biopsies comprising 14% of 
the total specimens analysed. More interestingly with log-trans-
formation, the distributions were ‘tightened’, so that the gross 
overlap was then reduced to 1%, or 38 biopsies. The literature 
presents a variety of optimum cut-off points ranging between 
20 and 40 IEL/100 enterocyte nuclei, as criteria in the diagnosis 
of CD (table 2). However, these levels were, surprisingly, deter-
mined from means and SD originating from some extremely 
small groups.11–18 In this study, we had the advantage of large 
numbers of CD and DC biopsies which were further evaluated 
through ROC curve analysis (figure 2). This offered an optimal 
cut-off point of 25 IEL/100 enterocytes, with a sensitivity of 
0.990 and specificity of 0.931, respectively; the area under the 
curve was 99.5%. Here, each point on the ROC curve represents 
a sensitivity/specificity pair for any threshold value chosen. With 
perfect discrimination (no overlap in the two distributions), the 
ROC curve should pass through the upper left-hand corner, indi-
cating a sensitivity and specificity of 100%. Our curve does not 
fulfil that criterion exactly, pointing to the inevitable overlap of 
IEL populations between both groups.
Using our derived ROC curve, we were able to further eval-
uate the currently existing published extremes (20–40 IEL) in 
the literature (table 2). Thus, for a high cut-off of 40 IEL, the 
sensitivity was reduced to 0.80 with a specificity of 1.000. At this 
level, the false-negative rate was 19.7%, representing a total of 
31 patients with CD who would have been missed. Conversely, 
with the lower cut-off of 20 IEL, the sensitivity was increased to 
0.995, although the specificity was now reduced to 0.081. This 
led to an 18.2% false-positive result, which would have repre-
sented 37 DC biopsies being incorrectly labelled as ‘possible 
CD’. Since the actual numbers of cases misdiagnosed at these 
outer IEL counts are very high, their inaccuracy as histopatho-
logical guidelines is clearly evident.
Both the numerical overlapping (figure 1) and the shape of 
the ROC curve (figure 2) confirmed our previously published 
assertion1 that IEL do not represent bimodally distributed 
populations. This was further confirmed by our cumulative IEL 
count, biopsy-on-biopsy (figure 3), indicative of a graded dose–
response by IEL to environmental (gluten) antigenic influence.19
By taking 25 IEL/100 enterocytes as the optimal distin-
guishing value, a significant reduction was seen in the numerical 
overlap between patients with CD and DC patients (figure 1). 
In most previously published series, this overlap has not previ-
ously received much in-depth analysis. Given that the IEL are 
not bimodally distributed, any proposed cut-off between DC 
and CD biopsies should be seen as arbitrary. In this series, the 
ROC-based overlap consisted of 3 CD women as false negatives 
and 12 DC as false positives. Although we had expected to have 
Figure 1 The numerical IEL counts (non-transformed) for the entire 
series of 401 specimens are shown for coeliac and disease control 
intestinal mucosae. The overlap of 56 between IEL counts for each 
population is stressed. Although when the same data are accumulated, 
biopsy-on-biopsy (figure 3), a perfectly shaped dose–response curve is 
obtained. IEL, intraepithelial lymphocytes.
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seen an increase in IEL counts in eastern biopsies, this impres-
sion was not borne out in practice (figure 4).
There were significant differences in the results between the 
UK and Romania (p=0.011) and between Italy and Romania 
(p<0.0001). We did not pursue these correlations since the 
numbers of biopsies per group were too small to deduce any 
insightful conclusions that could be safely drawn.
All 198 specimens analysed in this study fulfilled Marsh III 
criteria, of which 132 (66.7%) specimens were graded as IIIa, IIIb or 
IIIc. In graded specimens, a high proportion (60; 45%) were graded 
as Marsh IIIc. Conversely, 34 Marsh IIIa specimens comprised only 
26%, whereas the 38 remaining specimens (29%) were classified as 
Marsh IIIb. The grading report was not reportable for 66 of 198 
specimens, because six pathologists had already ceased grading this 
lesion and two others graded biopsies as a+b or b+c or even a+b+c. 
The IEL populations between these three groupings, however, were 
not significantly different (table 3).
Six groups submitted their counts as CD3+ totals, allowing the 
possibility of determining percentage counts for each Marsh III 
subdivision. Again, no differences were found (table 3) with the 
arithmetic mean, being 63 immunolabelled cells/100 enterocyte 
nuclei.
DISCuSSIOn
The results of this multicentre study across three continents indi-
cated that: (1) the optimal cut-off point between CD and DC 
mucosae was 25 IEL/100 enterocyte nuclei, (2) there was no 
substantial difference in IEL counts from countries across the 
Table 2 Summary of literature on IEL counts
Study Methods number of biopsies upper range Comments
Ferguson and Murray5 H&E staining, IEL/100 
enterocytes, 7 µm sections
40 40 Used controls, coeliac & autoimmune conditions, incorrect about 
normally distributed IEL, highest IEL count recorded: 155
Batman et al14 H&E staining, 5 µm sections 8 33 Study of HIV enteropathy
Hayat et al12 H&E staining,
4 µm sections
20 25 Counts made on uninterrupted length of epithelium >500 EC, controls 
defined only by a ‘normal’ sugar permeability
Mahadeva et al15 H&E staining, 3 µm sections 29 22 Major interest in normal villi with IEL infiltrate. Really difficult to infer 
group numbers here
Kakar et al16 H&E staining 12 39 Interest in normal villi with IEL infiltrates




In H&E sections, if IEL to EC ratio >5:1, do CD3 count
Biagi et al13 H&E staining 17 45 Major interest in promoting villous tip counts
Lähdeaho et al30 H&E staining 76 26 No reasons given for this cut-off value: referred to Ferguson and Murray5 
and Kuitunen et al31 who give no reference range




Establishing normal criteria by histology and immunocytology
Siriweera et al32 H&E staining 75 8 Retrospective study on 38 control and 37 coeliac specimens. Inexplicably 
small upper ranges for both groups
Notes: Here are tabulated some of the principal papers concerned with IEL counts in normal and diseased intestinal mucosae. Once identified in this way, it comes as a surprise 
that our perceptions of normality and of the accepted distinctions between normal and abnormal are so precariously based. Furthermore, the emphasis in some papers has been 
on the abnormal (HIV enteropathy), or with reference to a specific aspect (such as villus tip IEL), whereas in others, the actual numbers of patients are unclear, or a worked mean 
IEL±SD is not given. The very small size of some of the groups analysed should also be noted, since that has a major impact on the statistical ranges and confidence limits offered 
as diagnostic (with permission from Marsh & Heal.22, 
EC. epithelial cells; IEL, intraepithelial lymphocytes.
Figure 2 The receiver operating characteristic (ROC) curve for all 401 
biopsies employed in this study is shown here. If there had been no 
relationship between the two samples, the curve would have followed 
the diagonal line. Our ROC graph shows considerable between-group 
homogeneity, the area under the curve being 99.5%. However, the 
sensitivity axis does not pass through the upper-left corner, indicative of 
the overlap which is further examined in detail elsewhere.
Figure 3 The cumulative IEL count, biopsy-on-biopsy, is illustrated 
in this diagram. The curve does not reach 401 on account of the 
overlapping counts between CD and DC mucosae, the overlap between 
biopsies being indicated by the two vertical parallel lines. The shape of 
the curve resembles a dose–response (to luminal antigen) and clearly 
demonstrates the absence of any bimodality between the two IEL 
populations. CD, coeliac disease; DC, disease control; IEL, intraepithelial 
lymphocytes.
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Western hemisphere, (3) CD IEL counts are not normally distrib-
uted, although correction by log-transformation did not materially 
affect outcomes, (4) the cumulative IEL population, biopsy-on-bi-
opsy, is indicative of a graded dose–response and thus does not 
represent a bimodal response between CD and DC IEL, and that 
any proposed cut-off value is arbitrary and (5) the total number 
of IEL in graded Marsh III lesions (a, b and c) was identical 
throughout, as was also demonstrated with the (smaller) number 
of CD3+ labelled IEL.
The use of elevated IEL counts has, for several decades, facili-
tated the histological diagnosis of CD. The original study which 
highlighted this advance by Ferguson and Murray5 contains several 
misconceptions. First, the false conclusion that IEL are normally 
distributed. The data from our study reveal that error, together 
with the skewing in the CD distribution, as shown previously.19 
It should be noted that there was a marked difference between 
the overlap as expressed by the numerically bulked data (figure 1), 
compared with our log-transformed results (data not illustrated). 
Log-transformation does ‘tighten up’ the distributions, reducing 
overlapping from 47 to 38. However, irrespective of the theoret-
ical importance of this observation, from a practical point of view, 
the question arises whether, in routine practice, all suspected CD 
counts need to be log-transformed to provide the most critically 
based diagnostic information. Our analyses confirm that this is 
unnecessary, since log-transformation does not afford any materi-
ally different result. For example, the difference for DC distribu-
tion was only 2 IEL/100 enterocytes (figure 1), and for CD was 3 
IEL. This is an important outcome of our study, and certainly an 
important message for histopathologists.
Second, Ferguson and Murray took 40 IEL as their upper limit 
of normal which is one of the highest results published (table 2). 
Based on our ROC curve analysis, a count of 40 IEL/100 entero-
cytes has a markedly reduced sensitivity of 0.790, compared 
with 0.995, when using a 25 IEL cut-off. Our established value 
corresponds to that of Hayat et al’s12 study but whose outcome 
was based on an exceptionally low mean count of 11 IEL/100 
enterocytes. Indeed, their range was 2–26 IEL, so that with a SD 
of 7, their upper calculated limit of normal was 25 (11+14). It 
is interesting to note that they studied only 20 biopsies obtained 
from apparently ‘healthy’ subjects, defined by a ‘normal’ sugar 
permeability test. Their counts were also based on enumerating 
IEL along an uninterrupted length of 500 enterocytes, which to 
us seems a technical impossibility. Nor were there any compar-
isons with CD biopsies, so on these three grounds, their study 
cannot be regarded as a critical evaluation.
Third, Ferguson and Murray introduced the methodology of 
counting IEL against epithelial cells, the inaccuracy of which 
was demonstrated by a point-counting technique.20 These reve-
lations were subsequently confirmed by computerised morpho-
metric analysis which showed that IEL counts were likely to be 
overestimated twofold.
By calculating both the number of enterocytes and IEL present 
in a controlled unit of villous volume, the numerical discrepancy 
of the earlier counting technique was exposed.19 21 The flaw is in 
trying to obtain a meaningful result when both parameters (epithe-
lial cell and IEL populations) are independently changing. The 
absolute IEL count in untreated CD mucosae is not increased, 
although it appears elevated since the number of enterocytes on 
the surface of a Marsh stage III lesion is, comparatively, markedly 
reduced. Conversely, with Marsh I and Marsh II stage lesions, the 
increase in IEL is absolute, representing a truly elevated popula-
tion. Several groups have tried to establish definitive cut-off points. 
However, these papers exemplify the precarious background on 
which current practice rests, and which is clearly in need of revi-
sion. The question of a cut-off, and how to locate it, is of both 
theoretical and practical importance.
As evident from the published data, a range of values lying 
between the extremes of 20 and 40 IEL has been proposed. Beyond 
that, there have been no further attempts to obtain a more reliable 
answer. Using our ROC curve (figure 2), we were able to investi-
gate IEL values published in the literature. At the highest notional 
cut-off value of 40 IEL, we predicted that there would have been 
31 false negatives (coeliac cases undiagnosed), but without any 
false positives. On the other hand, at the lower 20 IEL level, there 
would have been 37 false positives and 1 (coeliac) false negative. In 
Figure 4 This diagram illustrates the individual measurements from 
biopsies sampled across the Western hemisphere (USA, UK, France (FR), 
Netherlands (NL), Italy (ITAL), Romania (ROM), Turkey (TURK) and Iran). 
Bars reflect mean±SD for disease control (open circles) and coeliac 
disease (closed circles). The two sets of horizontal dotted lines indicate 
the overall mean±SD for the two groups of biopsies studied. IEL, 
intraepithelial lymphocytes.






IIIa 36 54±14 10 60±11
IIIb 38 52±17 12 67±19
IIIc 63 55±21 14 62±31
Total 137 54±18 36 63±23
Statistics: H&E: IIIa vs IIIb, p=0.91; IIIa vs IIIc, p=0.96 IIIb vs IIIc, p=0.96. CD3+: IIIa vs 
IIIb, p=0.84; IIIa vs IIIc, p=0.92; IIIb vs IIIc, p=0.98.
Note. The subclassification of the Marsh III lesion has, to our knowledge, never been 
subject to critical analysis despite its widespread adoption, as almost a ‘matter of 
faith’. Here we show that the IEL counts across each of these subdivisions reveal no 
statistical differences. This is most worrying, since the subdivisions were supposed 
to represent specific, detectable and progressively deteriorating pathologies during 
the terminal phases of mucosal flattening. Moreover, despite smaller numbers, 
no detectable differences in CD3+ IEL were detected between the IIIa, b and c 
subdivisions of the specimens analysed, in parallel with other findings 28.
IEL, intraepithelial lymphocytes.
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comparison with our results (with 12 disease controls and 3 coeliac 
misdiagnosed), the values given in the literature fare badly. The 
important point to remember is that any cut-off is an arbitrarily 
fixed point. Nevertheless, given the large numbers of specimens 
examined in this study, together with their respective IEL popula-
tions, the results of our analysis probably represent the best result 
achievable and hence the most effective cut-off level of 25 IEL on 
H&E-stained sections for working practice.
However, in another recent publication, IEL counts were accu-
mulated from the preceding 40-year literature, yielding 607 sepa-
rate data points. In combining H&E-derived IEL counts from both 
studies (giving a total of 255 CD and 271 DC biopsies), ROC curve 
analysis provided an optimal cut-off of 26 IEL with 95.81% of the 
combined sample correctly identified. Marsh and Heal 22also found 
that separate ROC curve analyses for CD3+, and γδ+, IEL counts 
yielded less satisfactory cut-off points. Therefore, their results are 
consistent with the current Bucharest conclusion that H&E-de-
rived IEL counts are adequate for its purpose. These are extremely 
interesting new insights and of great help to routine histopatholo-
gists in being reassured that immunohistochemistry does not offer 
improved diagnostic certainty.
IEL populations represent graded intestinal responses to antigenic 
challenge. This has been experimentally demonstrated in treated 
patients after gluten challenge.19 Here we have again confirmed and 
revealed the dose–response curve to gluten across all the specimens 
studied (figure 3). On inspecting our data, we were a little surprised 
that IEL counts did not increase across the globe from America to 
the near Middle East (figure 4), which we had suspected.
The statistical differences that were demonstrable are probably 
of little significance and were not evaluated further. It is, however, 
noteworthy that the IEL count is dependent on a surprisingly large 
number of internal and external factors1 including age, genetic back-
ground, ethnicity, geocultural factors, diet, food sensitivities, para-
sites, chronic liver disease, infections, drugs, the maternal and local 
intestinal microbiomes, and recent travel.
The large numbers of biopsies employed in this work helped 
to reveal the extent to which false-negative and false-positive 
misdiagnoses are incurred. A histologically negative result for CD 
appears to have less impact, since the clinician can employ addi-
tional assessments including Human Leucocyte Antigen (HLA) 
typing, EMA, increased anti-tTG titres or even deamidated 
gliadin assays23 to aid the diagnosis. A more difficult issue occurs 
when a normal biopsy is misclassified as CD, since there may be 
no additional pointers to avoid imposition of a lifelong gluten-
free diet.
Finally, our study has cast more light on the subclassification of the 
Marsh stage III coeliac lesion that originated from Dutch studies24 25 
and later taken over by Oberhuber et al26 in a review without citing 
the studies behind it. The subdivision of Marsh III was introduced 
to demonstrate a correlation between serology and degrees of 
mucosal abnormalities that led to first description of seronegative 
CD concept.24 Within our total sample, 132 biopsies were contrib-
utory, but we were surprised that nearly one-half (60, or 46%) were 
classified as Marsh IIIc, whereas only 38 (29%) were considered 
Marsh IIIb, and even less, 34 (25%), as Marsh IIIa. It should also 
be observed that we found no significant differences between the 
IEL populations within any of these subgroups (table 3). Although 
this subclassification was supposed to provide a ‘standardised proce-
dure for mucosal classification’, no empirical measurements accom-
panied the modifications suggested, thus leaving this to subjective 
interpretation. A subsequent set of ‘guidelines for pathologists’, 
written by pathologists,27 offered micrographs of biopsies which did 
not correspond to those originally given. In a separate study of CD 
IEL and their immunohistological subtypes,28 no differences in the 
‘lymphogram’ in terms of the subclassification of Marsh stage III 
mucosae could be found. That would be inconsistent with the orig-
inal proposal that each subdivision supposedly represents a progres-
sively greater degree of mucosal involvement and damage. Previous 
detailed morphological studies with transmission and scanning 
electronic microscopy have further degraded this subclassification7 
by demonstrating their lack of relevance to mucosal architecture 
interpretation. A recent study from Australia which employed prin-
cipal component and discriminant analyses29 found that defined 
algorithms could accurately distinguish the major Marsh grades, 
but were unable to discriminate between any of the so-called Marsh 
IIIa, b and c sublesions. Together, this growing body of information 
seems to indicate that attempted subclassifications of Marsh stage 
III lesions have no intrinsic status or value, and therefore would best 
be abandoned.
In that regard, six contributory groups within this study had 
already abandoned this subclassification, whereas two other 
groups classified their biopsies with multiple combinations of 
a+b+c, indicating the impossibility, if not gross frustration, of 
forcing one subclassification to fit into one or the other category.
This might be an explanation for the anomalous finding 
that almost 50% of biopsies were classified as Marsh IIIc, with 
far less weight put on the other two subcategories. Clearly, if 
morphological, immunohistochemical or mathematically based 
analyses fail to reveal any major differences in the progressive 
degrees of tissue damage implied by this subclassification, then 
what value can emerge from its continued use? Equally strained 
is the growing habit of equating Marsh IIIa with so-called ‘partial 
villous atrophy’, Marsh IIIb with ‘subtotal villous atrophy’ and 
Marsh IIIc with ‘total villous atrophy’. Interestingly, in flat 
lesions, there is no evidence of an atrophic process, but only 
hypertrophic mucosal responses,1 and a striking absence of villi.
In summary, based on a large intercontinental study of IEL, 
involving over 400 biopsies, we have firmly established that 
a cut-off point of 25 IEL/100 enterocyte nuclei provides a very 
effective criterion for distinguishing CD Marsh III stage biopsies 
from DC tissues. No obvious trends in IEL counts were found in 
biopsies sampled from across the three continents. The CD IEL 
count is not normally distributed yet, as we have shown, this does 
not make any substantial difference to laboratory counting in the 
routine work of histopathologists. We found no differences when 
examining IEL populations throughout the three proposed subdi-
visions of the Marsh III lesion, suggesting that these subdivisions 
(a, b, c) are spurious, lacking any useful histopathological content, 
while offering no diagnostic or prognostic assistance whatsoever to 
the gastroenterologist.
Author affiliations
1Department of gastroenterology and Pathology, Milton Keynes University Hospital, 
Milton Keynes, UK
2Department of gastroenterology, luton and Dunstable University Hospital, luton, 
UK
3Wolfson college, University of Oxford, Oxford, UK
4gastroenterology and liver Diseases research centre, research institute for 
gastroenterology and liver Diseases, Shahid Beheshti University of Medical Sciences, 
tehran, the islamic republic of iran
5centre for Biostatistics, Faculty of Biology, academic Health Science centre, 
University of Manchester, Manchester, UK
6Department of gastroenterology, royal Derby Hospital, Derby, UK
7Department of Pathology, ankara University Medical School, ankara, turkey
8Department of gastroenterology, Warwick Hospital, Warwick, UK
9Service de Pathologie, centre de Biologie et Pathologie groupe Hospitalier du nord, 
Hospices civils de lyon, lyon, France
10University of Perugia Medical School, Perugia, italy
11Department of cellular Pathology, University Hospital Southampton nHS 
Foundation trust, Southampton, UK
12Department of Pathology, carol Davila University of Medicine and Pharmacy, 
Bucharest, romania
group.bmj.com on October 10, 2017 - Published by http://gut.bmj.com/Downloaded from 
7rostami K, et al. Gut 2017;0:1–7. doi:10.1136/gutjnl-2017-314297
Small bowel
13institute of Pathology Spedali civili, Brescia, italy
14internal Medicine and Pathology Unit, University of Palermo, giovanni Paolo ii 
Hospital, Sciacca, italy
15Department of Pediatrics and Surgical Pathology, Università Politecnica delle 
Marche, ancona, italy
16Department of Medicine and Surgery, Scuola Medica Salernitana, University of 
Salerno, Salerno, italy
17Departments of gastroenterology and Pathology, grigore t. Popa University of 
Medicine and Pharmacy, iasi, romania
18college of Medical, Veterinary and life Sciences, University of glasgow, glasgow, 
UK
19Digestive Disease research center, tehran University Medical Science, tehran, iran
20center for Prevention and Diagnosis of coeliac Disease and Pathology Unit, 
Fondazione irccS ca’ granda Ospedale Maggiore Policlinico, Milano, italy
21Department of Medical and Surgical Sciences, University of Bologna and Diagnostic 
and experimental, University of Bologna, Bologna, italy
22gastroenterology and Hepatology, Faculty of Medicine, Mashhad University 0f 
Medical Sciences, Mashhad, iran
23Pathology department, razavi hospital, Mashhad, iran
24Department of Pathology, Southern general Hospital, lanarkshire, UK
25Dudley group of Hospitals, Birmingham city University, Birmingham, UK
26Department of Hepatogastroenterology and Pathology, Free University Medical 
centre, amsterdam, the netherlands
27Department of Pathology and Medicine, Yale University School of Medicine, new 
Haven, USa
28Department of Pathology, Brigham & Women’s Hospital, Boston, USa
Correction notice this article has been corrected since it published Online First. 
the affiliations for Sauid ishaq, Masoud Sotoudeh and Stefano Ferrero have been 
updated.
Acknowledgements the authors would like to thank coeliac UK for making this 
study accessible by funding the open access publication fee.
Contributors Forty-one pathologists and gastroenterologists participated in this 
study by contributing towards pathology and clinical data, discussion on study 
concept, statistical analysis and writing and revising the manuscript. the study was 
designed during the second consensus meeting incorporated in the international 
course of Pathology in Bucharest. Kr designed and coordinated the study, organised 
the second consensus meeting with help and support from gBe. He also collected 
the data and wrote the first draft of the manuscript. HM performed the first statistical 
analysis and contributed towards data interpretation. cH performed the second 
analysis and MnM rewrote the draft and revised the interpretation of data. MWJ and 
gH critically reviewed the manuscript and MWJ contributed with clinical and histology 
data. gBe provided data and co-organised the consensus meeting. MHD and JJg 
contributed with their data, critical revision, drafting and finalising the manuscript. 
aSr, ae, VV, UV, MD, aca, anB, cci, Mrn and le contributed in the conceptualisation 
and design of the study, data collection and critical revision of the manuscript. BB, 
gBa, aBo, cca, aci, SF, MiF, MaF, ag, Kg, Si, aM, SM, rM, cJM, ir, aSi and MrZ 
contributed with their pathology and clinical data and revision of the manuscript.
Competing interests none declared.
ethics approval research and development/audit departments of countries 
involved and the ethical committee of research institute for gastroenterology and 
liver Diseases, Shahid Beheshti University of Medical Sciences, tehran under the 
following ethical number: ir.SBMU.riglD.rec.1395.87.
Provenance and peer review not commissioned; externally peer reviewed.
Open Access this is an Open access article distributed in accordance with the 
creative commons attribution non commercial (cc BY-nc 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work 
is properly cited and the use is non-commercial. See: http:// creativecommons. org/ 
licenses/ by- nc/ 4. 0/
© article author(s) (or their employer(s) unless otherwise stated in the text of the 
article) 2017. all rights reserved. no commercial use is permitted unless otherwise 
expressly granted.
RefeRences
 1 Marsh Mn, rostami K. What is a normal intestinal mucosa? Gastroenterology 
2016;151:784–8.
 2 Holmes gK, asquith P, Stokes Pl, et al. cellular infiltrate of jejunal biopsies in adult 
coeliac disease in relation to gluten withdrawal. Gut 1974;15:278–83.
 3 Marsh Mn. gluten, major histocompatibility complex, and the small intestine. a 
molecular and immunobiologic approach to the spectrum of gluten sensitivity (’celiac 
sprue’). Gastroenterology 1992;102:330–54.
 4 rostami K, aldulaimi D, Holmes g, et al. Microscopic enteritis: Bucharest consensus. 
World J Gastroenterol 2015;21:2593–604.
 5 Ferguson a, Murray D. Quantitation of intraepithelial lymphocytes in human jejunum. 
Gut 1971;12:988–94.
 6 Järvinen tt, Kaukinen K, laurila K, et al. intraepithelial lymphocytes in celiac disease. 
Am J Gastroenterol 2003;98:1332–7.
 7 Marsh Mn, Johnson MW, rostami K. Mucosal histopathology in celiac disease: a 
rebuttal of Oberhuber’s sub-division of Marsh iii. Gastroenterol Hepatol Bed Bench 
2015;8:99–109.
 8 Ubiali a, Villanacci V, Facchetti F, et al. is tcr gamma clonality assay useful to detect 
early celiac disease? J Clin Gastroenterol 2007;41:275–9.
 9 ludvigsson JF, Bai Jc, Biagi F, et al. Diagnosis and management of adult 
coeliac disease: guidelines from the British Society of gastroenterology. Gut 
2014;63:1210–28.
 10 United european gastroenterology. When is a coeliac a coeliac? report of a working 
group of the United european gastroenterology Week in amsterdam, 2001. Eur J 
Gastroenterol Hepatol 2001;13:1123–8.
 11 Veress B, Franzén l, Bodin l, et al. Duodenal intraepithelial lymphocyte-count 
revisited. Scand J Gastroenterol 2004;39:138–44.
 12 Hayat M, cairns a, Dixon MF, et al. Quantitation of intraepithelial lymphocytes in 
human duodenum: what is normal? J Clin Pathol 2002;55:393–4.
 13 Biagi F, luinetti O, campanella J, et al. intraepithelial lymphocytes in the villous tip: do 
they indicate potential coeliac disease? J Clin Pathol 2004;57:835–9.
 14 Batman Pa, Miller ar, Forster SM, et al. Jejunal enteropathy associated with 
human immunodeficiency virus infection: quantitative histology. J Clin Pathol 
1989;42:275–81.
 15 Mahadeva S, Wyatt Ji, Howdle PD. is a raised intraepithelial lymphocyte count 
with normal duodenal villous architecture clinically relevant? J Clin Pathol 
2002;55:424–8.
 16 Kakar S, nehra V, Murray Ja, et al. Significance of intraepithelial lymphocytosis in 
small bowel biopsy samples with normal mucosal architecture. Am J Gastroenterol 
2003;98:2027–33.
 17 Pellegrino S, Villanacci V, Sansotta n, et al. redefining the intraepithelial 
lymphocytes threshold to diagnose gluten sensitivity in patients with 
architecturally normal duodenal histology. Aliment Pharmacol Ther 
2011;33:697–706.
 18 nasseri-Moghaddam S, Mofid a, nouraie M, et al. the normal range of duodenal 
intraepithelial lymphocytes. Arch Iran Med 2008;11:136–42.
 19 crowe Pt, Marsh Mn. Morphometric analysis of intestinal mucosa. Vi—Principles in 
enumerating intra-epithelial lymphocytes. Virchows Arch 1994;424:301–6.
 20 guix M, Skinner JM, Whitehead r. Measuring intraepithelial lymphocytes, surface 
area, and volume of lamina propria in the jejunal mucosa of coeliac patients. Gut 
1979;20:275–8.
 21 crowe Pt, Marsh Mn. Morphometric analysis of small intestinal mucosa. 
iV. Determining cell volumes. Virchows Arch A Pathol Anat Histopathol 
1993;422:459–66.
 22 Marsh Mn, Heal cJ. evolutionary Developments in interpreting the gluten-induced 
Mucosal celiac lesion: an archimedian Heuristic. Nutrients 2017;9:213.
 23 Mooney PD, Wong SH, Johnston aJ, et al. increased detection of celiac disease 
with measurement of deamidated gliadin peptide antibody before endoscopy. Clin 
Gastroenterol Hepatol 2015;13:1278–84.
 24 rostami K, Kerckhaert J, von Blomberg BM, et al. Sat and serology in adult coeliacs, 
seronegative coeliac disease seems a reality. Neth J Med 1998;53:15–19.
 25 rostami K, Kerckhaert J, tiemessen r, et al. Sensitivity of antiendomysium and 
antigliadin antibodies in untreated celiac disease: disappointing in clinical practice. 
Am J Gastroenterol 1999;94:888–94.
 26 Oberhuber g, granditsch g, Vogelsang H. the histopathology of coeliac disease: 
time for a standardized report scheme for pathologists. Eur J Gastroenterol Hepatol 
1999;11:1185–94.
 27 Dickson Bc, Streutker cJ, chetty r. coeliac disease: an update for pathologists. J Clin 
Pathol 2006;59:1008–16.
 28 De andrés a, camarero c, roy g. Distal duodenum versus duodenal bulb: 
intraepithelial lymphocytes have something to say in celiac disease diagnosis. Dig Dis 
Sci 2015;60:1004–9.
 29 charlesworth rPg, andronicos nM, Scott Dr, et al. can the sensitivity of the 
histopathological diagnosis of coeliac disease be increased and can treatment 
progression be monitored using mathematical modelling of histological sections? – a 
pilot study. Adv Med Sci 2017;62:136–42.
 30 lähdeaho Ml, Kaukinen K, collin P, et al. celiac disease: from inflammation to 
atrophy: a long-term follow-up study. J Pediatr Gastroenterol Nutr 2005;41:44–8.
 31 Kuitunen P, Kosnai i, Savilahti e. Morphometric study of the jejunal mucosa in various 
childhood enteropathies with special reference to intraepithelial lymphocytes. J Pediatr 
Gastroenterol Nutr 1982;1:525–32.
 32 Siriweera e, Qi e, Yong e. Validity of intraepithelial lymphocyte counts in the diagnosis 
of celiac disease: a histopathological study. Int J Celiac Dis 2015;3:136–42.
group.bmj.com on October 10, 2017 - Published by http://gut.bmj.com/Downloaded from 
coeliac disease mucosal interpretation
lymphocyte counts, distribution & role in 
ROC-king onwards: intraepithelial
Zali and Amitabh Srivastava
Masoud Sotoudeh, Vincenzo Villanacci, Umberto Volta, Mohammad R 
Marie Robert, Ilaria Russo, Mohammad Rostami-Nejad, Angelo Sidoni,
Sherly Mathews, Roxana Maxim, Chris J Mulder, Andra Neefjes-Borst, 
Ghaffarzadehgan, James J Going, Sauid Ishaq, Alessandra Mandolesi,
Ferrero, Michelangelo Fiorentino, Marilena Fiorino, Azita Ganji, Kamran 
Ciobanu, Mihai Danciu, Mohammad H Derakhshan, Luca Elli, Stefano
Bozzola, Antonio Carroccio, Carlo Catassi, Carolina Ciacci, Alexandra 
Bancel, Gabrio Bassotti, Adrian Bateman, Gabriel Becheanu, Anna
Calvin Heal, Geoffrey Holmes, Arzu Ensari, David Aldulaimi, Brigitte 
Kamran Rostami, Michael N Marsh, Matt W Johnson, Hamid Mohaghegh,
 published online September 11, 2017Gut 
 http://gut.bmj.com/content/early/2017/09/16/gutjnl-2017-314297




This article cites 32 articles, 9 of which you can access for free at: 
Open Access
http://creativecommons.org/licenses/by-nc/4.0/non-commercial. See: 
provided the original work is properly cited and the use is
non-commercially, and license their derivative works on different terms, 
permits others to distribute, remix, adapt, build upon this work
Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
This is an Open Access article distributed in accordance with the Creative
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections




To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on October 10, 2017 - Published by http://gut.bmj.com/Downloaded from 
